Aurora Cannabis Inc. is fighting back against an unsolicited takeover attempt by U.S.-based Curaleaf Holdings, Inc., publicly urging shareholders to reject the deal and accusing its rival of trying to acquire the Canadian cannabis giant on the cheap using shareholder money.
In a strongly worded response, Aurora’s leadership said the offer materially undervalues the company and exposes Aurora’s investors to unacceptable financial risk. The Edmonton-based producer argued it is in a far stronger financial position than its would-be acquirer and questioned why shareholders should hand over control to a company carrying more than $1-billion in debt.
“We will not allow Curaleaf to use our own shareholders’ cash to finance this bid,” said Miguel Martin, Aurora’s executive chairman and chief executive. He accused Curaleaf of attempting to “acquire Aurora’s assets at a discount and shift material risks onto shareholders.”
A Battle of Financial Narratives
The public spat centres on a fundamental disagreement about who needs whom more. Aurora, once the highest-flying name in Canadian cannabis, has spent recent years restructuring under Martin’s leadership, shedding debt and streamlining operations. The company says it now sits debt-free with roughly $149-million in cash on hand.
Curaleaf, by contrast, is pitching itself as a larger, more diversified global platform with the scale to weather volatility in the cannabis sector. Its chairman and chief executive, Boris Jordan, said the combined company would offer Aurora shareholders “immediate value” alongside a stake in a much bigger enterprise.
Jordan said he remains “ready and willing to engage constructively” with management but claimed Aurora has refused to enter “meaningful talks” since the offer was made public. Aurora has not signalled any willingness to negotiate, doubling down on its rejection instead.
Details of the Offer
Curaleaf launched its bid last month, valuing each Aurora share at approximately US$4.00. The proposal consists of 0.3463 of a Curaleaf subordinate voting share and 75 US cents in cash, based on Curaleaf’s closing price on Aug. 10.
Aurora argues the math does not add up. In a presentation to shareholders, the company highlighted that Curaleaf holds more than $1-billion in debt and would effectively gain access to Aurora’s $149-million cash pile as part of any transaction, a transfer of value Curaleaf has not adequately explained, according to Aurora’s board.
Shares of Aurora were trading up slightly at $5.61 in late-morning trade on the Toronto Stock Exchange, suggesting investors were not rushing to dump the stock in favour of Curaleaf’s offer.
A Sector Watching Closely
The clash is being watched well beyond the two companies involved. Canada’s cannabis industry has spent years consolidating, and any merger of this size would create one of the largest operators in the global market.
Some analysts have questioned whether Curaleaf’s mix of cash and stock will be enough to win over Aurora shareholders, particularly given the company’s insistence that it is undervalued and that its turnaround strategy is gathering momentum. Others note that Curaleaf, with its larger footprint across the United States, brings assets and reach Aurora cannot easily replicate on its own.
For now, both sides are digging in. Aurora has launched a formal shareholder communications campaign, while Curaleaf is publicly signalling it has the resources and patience to keep pushing for a deal.
Why it Matters
This fight goes beyond boardroom politics. It is a referendum on the future direction of the global cannabis industry and a test of whether consolidation happens on the terms of indebted U.S. operators or leaner Canadian survivors. For Aurora shareholders, the decision is straightforward on paper but complex in practice: accept a modest premium and a foothold in a larger platform, or stick with a debt-free company betting it can stand on its own. The outcome will shape competition, jobs, and pricing power across North American cannabis for years to come.
